The Priority Review

Tag

AD04

1 story

Stories

  1. Clinical trials

    AmyriAD acquires AD04 Alzheimer's program from ADvantage

    AmyriAD announced the acquisition of the AD04 program, a Phase 2b-ready investigational drug targeting neuroinflammation in mild Alzheimer's disease. The program was derived from a 332-patient Phase 2 vaccine study and is planned to enter Phase 2b development under the Innovative Licensing and Access Pathway.